Product Details
Synonyms
HMGB1, HMG1, HMG3, SBP-1
Source
Human HMGB1 Protein, Mouse IgG2a Fc Tag (HM1-H5255) is expressed from human 293 cells (HEK293). It contains AA Gly 2 - Glu 215 (Accession # P09429-1).
Predicted N-terminus: Glu
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the N-terminus.
The protein has a calculated MW of 51.6 kDa. The protein migrates as 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human HMGB1 Protein, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-CELL BASE

Human HMGB1 Protein, Mouse IgG2a Fc Tag (Cat. No. HM1-H5255) stimulates production of TNF-α in Raw-246.7 cells. The EC50 for this effect is 13.18 μg/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
High Mobility Group Protein B1
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















